KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Current Assets (2016 - 2025)

Abbott Laboratories' Current Assets history spans 17 years, with the latest figure at $26.0 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 9.89% year-over-year to $26.0 billion; the TTM value through Dec 2025 reached $26.0 billion, up 9.89%, while the annual FY2025 figure was $26.0 billion, 9.89% up from the prior year.
  • Current Assets for Q4 2025 was $26.0 billion at Abbott Laboratories, up from $24.8 billion in the prior quarter.
  • Across five years, Current Assets topped out at $26.0 billion in Q4 2025 and bottomed at $21.8 billion in Q1 2021.
  • The 5-year median for Current Assets is $23.6 billion (2023), against an average of $23.8 billion.
  • The largest annual shift saw Current Assets surged 40.77% in 2021 before it dropped 10.13% in 2023.
  • A 5-year view of Current Assets shows it stood at $24.2 billion in 2021, then grew by 4.06% to $25.2 billion in 2022, then decreased by 10.13% to $22.7 billion in 2023, then grew by 4.35% to $23.7 billion in 2024, then rose by 9.89% to $26.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Current Assets are $26.0 billion (Q4 2025), $24.8 billion (Q3 2025), and $24.5 billion (Q2 2025).